Cargando…

Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer

PURPOSE: Triple-negative breast cancer (TNBC) represents a major clinical challenge due to its aggressive and metastatic behavior and the lack of available targeted therapies. Therefore, therapeutic strategies are needed to improve TNBC patient management. Recently, atezolizumab and nab-paclitaxel c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Seung Eun, Park, Ha Young, Lim, So Dug, Han, Hye Seung, Yoo, Young Bum, Kim, Wan Seop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311361/ https://www.ncbi.nlm.nih.gov/pubmed/32595992 http://dx.doi.org/10.4048/jbc.2020.23.e37

Ejemplares similares

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
por: Cha, Yoon Jin, et al.
Publicado: (2021)

CT‐guided transthoracic needle biopsy for evaluation of PD‐L1 expression: Comparison of 22C3 and SP263 assays
por: Beck, Kyongmin S., et al.
Publicado: (2019)

PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs
por: Park, Yujun, et al.
Publicado: (2020)

SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3
por: Pang, Jia-Min B., et al.
Publicado: (2021)

Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
por: Xu, Haipeng, et al.
Publicado: (2017)

Evaluating programmed death‐ligand 1 (PD‐L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study
por: Cerbelli, Bruna, et al.
Publicado: (2021)

External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different
por: Dodson, Andrew, et al.
Publicado: (2019)

Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
por: Li, Yijin, et al.
Publicado: (2021)

SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
por: Baek, Seung Ho, et al.
Publicado: (2022)

Fatty acid synthetase expression in triple-negative breast cancer
por: Park, Jin Hee, et al.
Publicado: (2022)

PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers
por: Compérat, Eva, et al.
Publicado: (2021)

Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability
por: Ahn, Soomin, et al.
Publicado: (2021)

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay
por: Scorer, Paul, et al.
Publicado: (2018)

Overexpression of FRAT1 protein is closely related to triple-negative breast cancer
por: Nam, Sang Eun, et al.
Publicado: (2022)

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2021)

Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms
por: Sigurjonsdottir, Gudbjörg, et al.
Publicado: (2023)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
por: Vennapusa, Bharathi, et al.
Publicado: (2019)

PD-L1 Testing in Urothelial Carcinoma: Analysis of a Series of 1401 Cases Using Both the 22C3 and SP142 Assays
por: Evans, Harriet, et al.
Publicado: (2022)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
por: Maule, Jake G, et al.
Publicado: (2022)

Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives
por: Kim, Sue Youn, et al.
Publicado: (2022)

Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
por: Krawczyk, Paweł, et al.
Publicado: (2017)

High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer
por: Lee, Seung Eun, et al.
Publicado: (2021)

Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma
por: García, Alejandro, et al.
Publicado: (2020)

Triple DC SP2T
por: Bento, J
Publicado: (2000)

Seroprevalence of Trichinella sp. in Wild Boars (Sus scrofa) from Yanggu-gun, Gangwon-do, Korea
por: Lee, Hye-Jung, et al.
Publicado: (2015)

Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review
por: Sakakibara, Ayako, et al.
Publicado: (2021)

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
por: Zhou, Caicun, et al.
Publicado: (2023)

Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N
por: Smith, Jacquelyn, et al.
Publicado: (2016)

Penicillium ulleungdoense sp. nov. from Ulleung Island in Korea
por: Choi, Doo-Ho, et al.
Publicado: (2020)

Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation–Positive Lung Adenocarcinoma
por: Kim, Taehee, et al.
Publicado: (2020)

Comments on the Article by Miura et al.: “Comparable Clinical Benefit Between Different Subsets Selected by PD-L1 22C3 and SP142 Tests”
por: Yatabe, Yasushi
Publicado: (2023)

Clinical significance of ≥ 50% PD‐L1 expression with the SP263 monoclonal antibody in non‐small cell lung cancer patients
por: Li, Wenbin, et al.
Publicado: (2018)

Preoperative RAS Mutational Analysis Is of Great Value in Predicting Follicular Variant of Papillary Thyroid Carcinoma
por: Hwang, Tae Sook, et al.
Publicado: (2015)

Talaromyces columbinus sp. nov., and Genealogical Concordance Analysis in Talaromyces Clade 2a
por: Peterson, Stephen W., et al.
Publicado: (2013)

Effect of storage time of paraffin sections on the expression of PD-L1 (SP142) in invasive breast cancer
por: He, Jiankun, et al.
Publicado: (2023)

Development of an Ammonium Sulfate DNA Extraction Method for Obtaining Amplifiable DNA in a Small Number of Cells and Its Application to Clinical Specimens
por: Oh, Seo Young, et al.
Publicado: (2013)

Ligand-Promoted Alkylation of C(sp(3))–H and C(sp(2))–H Bonds
por: Zhu, Ru-Yi, et al.
Publicado: (2014)

Theoretical investigation on the effect of the ligand on bis-silylation of C(sp)–C(sp) by Ni complexes
por: Hui, Li, et al.
Publicado: (2022)

A Case of Multifocal Papillary Thyroid Carcinoma Consisting of One Encapsulated Follicular Variant with BRAF K601E Mutation and Three Conventional Types with BRAF V600E Mutation
por: Kim, Wook Youn, et al.
Publicado: (2013)

SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3
por: Nakahama, Kenji, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nacln9csav2geb6k8urdgpfhd9